Our study defines the mechanistic impact of LCK and potentially other non-receptor tyrosine kinases in regulation of HR repair that is apparently crucial to ovarian cancer’s response to chemotherapy and PARP inhibitors. The gene discussed is NTRK1; the disease is ovarian carcinoma.